Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FERTINEX vs ANDEMBRY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Follitropin beta, a recombinant form of human follicle-stimulating hormone (FSH), binds to the FSH receptor on ovarian granulosa cells and testicular Sertoli cells, stimulating follicular development and maturation in women and spermatogenesis in men.
Binds to androgens, progesterone, and estradiol, inhibiting their effects on hormone-responsive tissues; also binds to microtubules and inhibits tubulin polymerization.
Ovulation induction in anovulatory women with polycystic ovary syndrome (PCOS) who have failed to respond to clomiphene citrate,Controlled ovarian hyperstimulation for assisted reproductive technologies (ART) such as in vitro fertilization (IVF),Hypogonadotropic hypogonadism in men
Castration-resistant prostate cancer (chemotherapy-naïve or docetaxel-treated),Metastatic castration-resistant prostate cancer
For ovulation induction: 75-150 IU subcutaneously or intramuscularly once daily for 7-12 days; for spermatogenesis: 75-150 IU subcutaneously or intramuscularly 3 times per week.
ANDEMBRY (capivasertib) 400 mg orally twice daily, taken with or without food, in combination with fulvestrant. Continue until disease progression or unacceptable toxicity.
Terminal elimination half-life is approximately 24-36 hours in patients with normal renal function, supporting once-daily dosing.
Terminal elimination half-life is 12-15 hours in healthy adults; may be prolonged up to 20-25 hours in patients with moderate to severe hepatic impairment.
Metabolized primarily via the liver and kidneys; exact enzymes not fully characterized, but involves hepatic degradation and renal excretion.
Hepatic via CYP3A4; active metabolites include abiraterone sulfate, abiraterone N-oxide, and abiraterone glucuronide.
Primarily renal excretion of unchanged drug (80-90% of administered dose), with the remainder excreted as metabolites in urine and feces.
Primarily renal excretion of unchanged drug (approximately 70-80%) and as metabolites (10-15%); biliary/fecal elimination accounts for less than 10%.
Approximately 60-70% bound to plasma proteins, primarily albumin.
Approximately 95% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Vd is approximately 0.3-0.5 L/kg, indicating distribution mainly into extracellular fluid.
Volume of distribution is 0.6-0.8 L/kg, indicating distribution into total body water and some tissue binding.
Subcutaneous: ~70% relative to intravenous; intramuscular: ~90% relative to intravenous.
Oral bioavailability is 85-90%; intravenous administration yields 100% bioavailability.
No specific dosing guidelines; use with caution in severe renal impairment (Cr Cl <30 m L/min) due to limited data; consider reduced dose or extended interval.
No dose adjustment required for mild-to-moderate renal impairment (Cr Cl ≥30 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min) or end-stage renal disease; avoid use.
No specific dosing guidelines; use with caution in severe hepatic impairment (Child-Pugh class C) due to limited data; consider reduced dose.
Mild hepatic impairment (Child-Pugh A): no dose adjustment. Moderate hepatic impairment (Child-Pugh B): reduce dose to 320 mg orally twice daily. Severe hepatic impairment (Child-Pugh C): not recommended.
For delayed puberty (males): 75-150 IU subcutaneously or intramuscularly 3 times per week; adjust based on testosterone response. For cryptorchidism: 1000-1500 IU subcutaneously or intramuscularly 2-3 times per week for 4-6 weeks; not weight-based but age-adjusted.
Safety and efficacy not established in pediatric patients (<18 years); no recommended dose.
Elderly patients are not typically candidates for FERTINEX; no specific dose adjustments recommended due to lack of use; monitor for comorbidities and potential hypersensitivity.
No specific dose adjustment required based on age. Monitor renal function and for increased risk of adverse events (e.g., diarrhea, hyperglycemia) in elderly patients.
FERTINEX should only be used by physicians with expertise in infertility treatment. Ovarian hyperstimulation syndrome (OHSS) may occur, which can be severe and result in ovarian enlargement, pelvic pain, ascites, pleural effusion, and thromboembolic events. Multiple gestation increases the risk of adverse maternal and perinatal outcomes.
None.
Risk of ovarian hyperstimulation syndrome (OHSS), which may be severe and require hospitalization,Increased risk of multiple gestation (twins, triplets, etc.),Ovarian torsion reported,Potential for ovarian enlargement and cyst formation,Thromboembolic events, especially in patients with risk factors,Should not be used in patients with primary ovarian failure, uncontrolled thyroid/adrenal dysfunction, or sex hormone-dependent tumors
Hepatotoxicity, mineralocorticoid excess, cardiovascular events, adrenal insufficiency, and bone marrow suppression.
Pregnancy,Lactation,Primary ovarian failure (elevated FSH levels),Uncontrolled thyroid or adrenal dysfunction,Sex hormone-dependent tumors (e.g., breast, ovarian, uterine),Hypersensitivity to follitropin beta or any component of the formulation
Hypersensitivity to abiraterone acetate or any component, severe hepatic impairment (Child-Pugh C), and women who are or may become pregnant.
No specific food interactions. Maintain a balanced diet rich in folic acid (400-800 mcg/day) to reduce risk of neural tube defects. Avoid excessive alcohol and caffeine.
ANDEMBRY can be taken with or without food. However, grapefruit and grapefruit juice may increase trofinetide levels; avoid concurrent consumption. No other significant food interactions reported.
Fertinex (urofollitropin) is associated with a Category X risk in pregnancy. Administration during pregnancy may cause fetal harm, including congenital malformations (neural tube defects, limb defects) and spontaneous abortion. Use is contraindicated in pregnant women.
Category X. First trimester: Major congenital malformations (neural tube defects, craniofacial abnormalities). Second/third trimester: Spontaneous abortion, fetal death, growth restriction. Contraindicated in pregnancy.
Safety during breastfeeding has not been established. Excretion in human milk is unknown; no M/P ratio available. Due to potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during treatment.
Excreted in human milk; M/P ratio unknown. Potential for serious adverse effects in nursing infant. Contraindicated during breastfeeding.
No dose adjustments are indicated as Fertinex is contraindicated in pregnancy. Use should be discontinued if pregnancy is confirmed.
Do not use in pregnancy. No dose recommendations available; contraindicated.
FERTINEX (urofollitropin) is a purified FSH product used for ovulation induction. Monitor ovarian response via serum estradiol levels and transvaginal ultrasound to assess follicle size and number. Adjust dose based on response to minimize OHSS risk. Administer IM or SC after reconstitution. Use caution in patients at risk for thromboembolism.
ANDEMBRY (trofinetide) is indicated for the treatment of Rett syndrome. Administer orally twice daily with or without food. Monitor for diarrhea and vomiting, which are common adverse effects; consider dose reduction or temporary discontinuation if severe. Assess liver enzymes and bilirubin before and during treatment due to potential hepatotoxicity. Avoid use in patients with severe hepatic impairment. Do not crush or chew capsules; for patients unable to swallow, sprinkle contents onto soft food and administer immediately.
FERTINEX is a hormone injection given under the skin or into a muscle to help you ovulate.,You will need training on how to inject the medication and dispose of needles safely.,Common side effects include headache, bloating, and injection site reactions.,Seek immediate medical attention if you experience severe pelvic pain, sudden weight gain, or shortness of breath.,Avoid alcohol and limit caffeine intake during treatment.,Report any signs of ovarian hyperstimulation syndrome (OHSS) such as nausea, vomiting, or decreased urination.
Take ANDEMBRY exactly as prescribed, twice daily with or without food.,If you miss a dose, skip it and take the next dose at the regular time; do not double the dose.,Common side effects include diarrhea and vomiting; inform your doctor if these become severe or persistent.,Avoid alcohol while taking this medication as it may increase the risk of liver injury.,Report any signs of liver problems such as yellowing of skin or eyes, dark urine, or abdominal pain.,Do not crush or chew the capsules; if you have trouble swallowing, open the capsule and mix the contents with a small amount of soft food (e.g., applesauce) and take immediately.,Keep this medication out of reach of children and store at room temperature away from moisture.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FERTINEX vs ANDEMBRY, answered by our medical review team.
FERTINEX is a Gonadotropin that works by Follitropin beta, a recombinant form of human follicle-stimulating hormone (FSH), binds to the FSH receptor on ovarian granulosa cells and testicular Sertoli cells, stimulating follicular development and maturation in women and spermatogenesis in men.. ANDEMBRY is a Gonadotropin that works by Binds to androgens, progesterone, and estradiol, inhibiting their effects on hormone-responsive tissues; also binds to microtubules and inhibits tubulin polymerization.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FERTINEX and ANDEMBRY depend on the specific clinical indication. These are both Gonadotropin agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FERTINEX is: For ovulation induction: 75-150 IU subcutaneously or intramuscularly once daily for 7-12 days; for spermatogenesis: 75-150 IU subcutaneously or intramuscularly 3 times per week.. The standard adult dose of ANDEMBRY is: ANDEMBRY (capivasertib) 400 mg orally twice daily, taken with or without food, in combination with fulvestrant. Continue until disease progression or unacceptable toxicity.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FERTINEX and ANDEMBRY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FERTINEX is classified as Category C. Fertinex (urofollitropin) is associated with a Category X risk in pregnancy. Administration during pregnancy may cause fetal harm, including congenital malformations (neural tube d. ANDEMBRY is classified as Category C. Category X. First trimester: Major congenital malformations (neural tube defects, craniofacial abnormalities). Second/third trimester: Spontaneous abortion, fetal death, growth res. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.